News Desk, Amar Ujala, New Delhi
Published by: Amit Mandal
Updated to Friday, 17 December 2021 8:23 PM IST
Relief news came in the wake of increasing cases of new variant omicron cases of corona virus in the country.
Vaccine for Kovid 19
– Photo: Social Media
Listen to the news
The corona vaccine Kovovax of the Serum Institute of India has been approved by the World Health Organization. The Kovid-19 vaccine Kovovax has been approved by the WHO for emergency use, said Adar Poonawala, CEO of the company. This vaccine is designed for children 12 to 17 years of age.
The COVID19 vaccine Covovax is now WHO approved for emergency use, showing excellent safety and efficacy, said Adar Poonavalla, CEO, Serum Institute of India. pic.twitter.com/r5rvn9n8K0
– ANI (ANI) December 17, 2021
Vaccine for children 12 to 17 years
In fact, the Serum Institute is an American pharmaceutical company preparing a vaccine for children called ‘Kovovax’ in the country. Previously, the Director General of Medicines of India (DCGI) approved the serum to test the vaccine for children aged 12 to 17 years. The serum was also tested on 100 children. Test data provided to DCGI.
Only Joykov-D was allowed
In India, only the Zykhov-de vaccine of Zydus cadillac is approved for emergency use in children and adults over 12 years of age.
Kovovax effective 89.3%
The Kovovax vaccine has been tested in the UK in the UK, with an effect rate of 89.3%. Serum contracted Novavox for 200 million doses. Earlier, the Serum Institute of India had also entered into an agreement with Estroneca, a maker of the CoviShield vaccine in India after the trial.